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Falls pose a signiﬁcant health risk for nursing home residents and are associated with depression and
medical treatments for depression. Data on falls as an adverse event to psychosocial treatments are
lacking. We examined risk of falls as an adverse event in a clinical trial of a behavioral treatment for
depression. Participants were 82 depressed nursing home residents. Adverse events were recorded at
each research contact. We used the rate ratio based on the respective incidence densities in the treat-
ment and control groups to measure association between fall rate and treatment. The treatment group
had almost six times higher risk of falls than the control group, a statistically signiﬁcant association.
Findings suggest that it may be of value to include statistical analysis of falls as adverse events in trials of
behavioral interventions for depression.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Falls are a serious health event for older adults, and affect
approximately two thirds of nursing home residents [10]. Depres-
sion is common in nursing homes and is associated with risk of falls
[5]. Medical treatments for depression are also associated with
increased risk of falls [4,13]. Adverse events are not frequently
analyzed in clinical trials for behavioral interventions, and little is
known about falls as an adverse event secondary to psychosocial
treatments for depression. As a part of our data safety and man-
agement plan in a clinical trial of a behavioral intervention for
depression [9], we tracked and analyzed adverse events. The pur-
pose of the present study was to assess the risk of falls associated
with a psychosocial depression treatment.1. Method
We analyzed data from a cluster-randomized controlled trial of a
10-week psychosocial treatment for depression designed to in-
crease activation through increasing pleasant events (See Refs. [8,9]
for primary outcomes and clinical trial details). Brieﬂy, 23 nursing
facilities from Kentucky and Indiana were randomly assigned to
either the experimental or treatment-as-usual (TAU) conditions.
There were 336 residents in the participating nursing homes whoInc. This is an open access article uwere eligible by screening; 157 refused participation and 150 res-
idents provided informed consent. Of those, 82 were eligible after a
more extensive assessment to determine depression diagnosis
(inclusion criterion) and exclude those with Mini-Mental State
Examination scores below 14 (those unable to complete study
measures); 42 were randomized to the experimental group, and 40
to the control group. Participants were assessed at baseline, post-
treatment, and at 3- and 6-month follow-ups.1.1. Measures
During a two-week baseline assessment and the 10-week
intervention phase, research staff met with participants for at least
one visit per week. Visits with treatment recipients were for
30e60min intervention sessions. Visits with TAU participants were
for 5e30 min, to collect data on current mood and physical events
occurring during the previous week. For all participants there were
two brief visits during the two-week follow-up periods at 3 months
and at 6 months. Each time a research staff member was in contact
with a participant they completed a checklist of possible adverse
events, which included the following: participant complaint of fa-
tigue related to the intervention, conﬁdentiality breach, increased
depression severity, suicidal ideation, severe medical set-back (e.g.,
hospitalization, pneumonia), resident died, falls, or “other.” When
research staff became aware of adverse events from nursing home
staff or other sources, they also completed this checklist. Researchnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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related or unrelated to the study activities. Adverse event ratings
were also reviewed quarterly by an independent data safety
monitor.
At baseline and follow-up assessments, we extracted the
following from the medical record: demographic information,
physical functioning, number of medications, and medical di-
agnoses. Research staff also reviewed medication records for use of
antidepressant and other psychotropic medications.1.2. Participants
Participants had a mean age of 75.16 (SD ¼ 12.11), a mean of
11.56 years of education (SD ¼ 3.35), and had been in the facility an
average of 37.70 months (SD ¼ 74.56). The sample was 34.6% men
and 92.6% white of European origin. All had a depressive diagnosis
determined at baseline via a structured clinical interview con-
ducted by a research psychologist. The participants had an average
of 9.31(SD ¼ 4.20) non-mental health medical diagnoses and over
81% were receiving antidepressant medications. Baseline compar-
isons of the experimental and TAU groups on demographics and
health variables showed that the groups were similar with the
exception that the experimental group had fewer days on an an-
tidepressant at baseline (t ¼ 2.18, DF ¼ 54, p ¼ 0.034), more edu-
cation (t ¼ 2.46, DF ¼ 60, p ¼ 0.017), and a larger number of
physician visits in the three months prior to baseline assessment
(t ¼ 2.56, DF ¼ 6.6, p ¼ 0.022) than the TAU group. The mean
duration of antidepressant usage for the primary antidepressant
was approximately 9 months.1.3. Data analyses
Because the amount of follow-up varied greatly among study
participants, we used the rate ratio based on the respective inci-
dence densities in the two groups as the measure of association so
that the number of person-days could be taken into account.
Separately for each adverse event, exact inferential methods for the
ratio of two Poisson parameters were used to ﬁnd a 95% conﬁdence
interval for the true rate ratio, and to test the null hypothesis that
the true rate ratio was equal to one. The mid-P adjustment was
used to reduce the conservatism of the exact methods [1]. Hy-
pothesis tests were two-tailed, and were performed using a sig-
niﬁcance level of 0.05. All statistical analyses were performed using
[12]; Cytel Software Corp., Cambridge, MA).Table 1
All adverse events by treatment group.
Adverse event Group # of eve
Fall Treatment 11/10,0
Control 2/10,68
Resident complained of fatigue related to intervention Treatment 1/11,25
Control 1/11,11
Increased depression severity Treatment 1/11,51
Control 6/10,41
Suicidal ideation Treatment 3/11,08
Control 2/10,62
Severe medical set-back Treatment 5/10,81
Control 9/10,70
Resident died Treatment 7/11,37
Control 7/11,25
Other Treatment 8/10,31
Control 13/93662. Results
Table 1 shows the adverse events data recorded during the
project; no adverse event other than falls was signiﬁcantly different
between the two groups. (The difference between groups on
“increased depression severity” approached signiﬁcance; as might
be expected given the results of the clinical trial [9] the control
group had more recorded instances of this adverse event). There
were 13 falls reported over 20,739 person-days of follow-up, or an
average of 252.91 days per participant (range: 9e336 days). Seven
participants fell once, and three participants fell twice. Most par-
ticipants did not fall, but 11 falls were experienced by members of
the treatment group, as compared to only 2 falls in the TAU group (2
individuals, one fall each). The fall rate in the treatment group was
nearly 6 times that of the control group, an association that was
statistically signiﬁcant.
Participant time in the study ranged from 10 to 101 days at the
time of their ﬁrst fall. The mean elapsed time in the study for all
falls was 73.31 days (SD ¼ 43.68); most of the treatment group falls
occurred during the last 3 weeks of treatment or the 3 months
following. Two of the falls were coded as directly related to treat-
ment activities.3. Conclusion
Our ﬁndings support the hypothesis that a psychosocial treat-
ment for depression can increase the risk of falls in nursing home
patients, and highlight the importance of measuring and analyzing
adverse events in behavioral trials. The participants in this ran-
domized, controlled trial who received the active interventionwere
almost six times more likely to fall than those in the treatment as
usual condition. This study involved secondary analysis of a clinical
trial, and limitation on power prevented us from performing
additional statistical analyses to examine concurrent risk factors.
Further, ascertainment of falls is not straightforward (e.g., [7]), and
our method of recording adverse events could have resulted in falls
being missed. Minor falls that did not result in patient injury or
distress may not have been reported to the research staff. Also,
there was no weekly monitoring between follow-up periods, so
falls that occurred during those periods, unless severe, may have
been missed. These limitations may have led to underestimating
falls, especially minor, non-injury falls. Because most falls that we
recorded occurred during the 12 weeks when all participants were
assessed weekly, our data only support the hypothesis that the risk
of falling is increased during the active treatment period. Having
better data about falls during the follow-up period could helpnts/days of person-time Rate Rate ratio (95% C.I.) P-value
52 0.001094 5.85 (1.45e38.84) 0.010
7 0.000187
6 0.000089 0.99 (0.03e38.51) 0.994
5 0.000090
0 0.000087 0.15 (0.01e1.02) 0.053
4 0.000576
9 0.000271 1.44 (0.21e12.08) 0.722
2 0.000188
8 0.000462 0.55 (0.17e1.64) 0.293
7 0.000841
1 0.000616 0.99 (0.33e2.95) 0.985
5 0.000622
7 0.000775 0.56 (0.22e1.35) 0.199
0.001388
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falls post-treatment. This is an important question clinically, as it
speaks to the need for ongoing monitoring of risk of falls after
treatment termination.
The participants in the current study shared risk factors for falls,
including depression, multiple chronic illnesses, functional
impairment, and antidepressant medication. Even with all of these
risk factors in common, those treatedwith an effective psychosocial
treatment for depression had a signiﬁcantly higher rate of falls than
those who were not. If replicated, these ﬁndings have both clinical
and research implications. In terms of clinical practice, it may be
important for mental health practitioners to consider risk of falls
during any treatment for depression, to assess regularly for safety,
and to consider whether treatment for depression should be
augmented by fall prevention practices. In terms of research, falls
should be tracked as a potential adverse event in psychosocial
treatment studies of depression, especially during treatment and
follow-up periods. More generally, this research suggests that there
could be value in monitoring and analyzing adverse events for
behavioral interventions, a practice that is rarely reported.Funding
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